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Risk of bleeding and transfusion in liver transplantation (LT) are determined by se-
verity of liver disease, surgical technique, pre-
operative hemoglobin value and antifibrinolitic 
therapy.1-4 In cirrhosis, despite the low levels 
of haemostatic proteins, thrombin generation 
is preserved.5 As a result of thrombin action, 
large amounts of fibrinogen are captured by 
the platelet glycoprotein IIb-IIIa receptor and 
converted to fibrin, which is polymerized by 
thrombin-activated FXIII and simultaneously 
cross-linked by alfa2-antiplasmin to stabilize 
the thrombus.6 Failing in fibrin polymerization 
facilitates the release of thrombin and factor X 
from the local thrombus to systemic circula-
tion, promoting the factor consumption and 
surgical bleeding.7
Correlation of conventional coagulation tests 
and bleeding events during LT still remains un-
clear.8 Two main factors influence the level of 
plasma fibrinogen during LT: consumption re-
lated to the coagulation process because of bleed-
ing and hemodilution mainly at reperfusion 
of the liver graft. We hypothesize that keeping 
confounders factors for transfusion identical, pa-
tients with a preoperative plasma fibrinogen level 
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Aim. Risk of bleeding in liver transplantation is determined by surgical technique, preoperative hemoglobin and 
antifibrinolitic therapy. We hypothesize that keeping these confounders factors identical, preoperative plasma fi-
brinogen level of ≤2 g/L influenced on blood product requirements.
Methods. Adult patients underwent orthotropic liver transplantation (LT) during the period between January 1998 
and December 2009. Cases were selected according to a propensity matching analysis meeting the following crite-
ria: surgical vena cava preservation, tranexamic acid administration and hemoglobin range between 90 to 120 g/L. 
Intraoperative management was protocolized. The main variable was the percentage of patients that do not require 
red blood cells (RBC’s).
Results. Six hundred sixty-four patients with LT, 208 excluded, 266 who cannot be matched, the analysis was per-
formed on 190 patients. Two cohorts: Low fibrinogen (≤2 g/L) (61 cases) and standard fibrinogen (>2 g/L) (129 
cases) were analyzed. Preoperative platelet count (73.5±52 vs.. 104±65; 103/mm3) was different in contrast to the 
hemoglobin (104.2±8.6 vs. 105.6±8.3; g/L). Use of RBC’s resulted significantly higher in the low fibrinogen group 
(median, 3 vs. 2). The number of patients with no blood product requirements was fewer in the low fibrinogen group 
(8 cases, 13% vs. 45 cases, 35%). The critical level of plasma fibrinogen (1 g/L) was reached after graft reperfusion in 
7 cases (5.5%) in the standard fibrinogen group vs. 24 cases (39%) in the low fibrinogen group.
Conclusion. Our data suggest that preoperative plasma fibrinogen level of ≤ 2 g/L increases requirements for blood 
products during the surgical procedure of liver transplantation. (Minerva Anestesiol 2013;79:1-2)
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of ≤2 g/L will increase surgical bleeding and lead 
to increase requirements for blood products.
Materials and methods
Adult patients undergoing orthotopic liver 
transplantation from deceased donors during 
the period between January 1998 and December 
2009 at one center were considered for analy-
sis. The Clinical Research Ethics Committee 
(IRB00005523) has revised this manuscript for 
its publication.
Cases were selected according to a propensity 
matching analysis meeting all three following 
criteria: surgical technique of vena cava preser-
vation, antifibrinolitic therapy and preopera-
tive hemoglobin range remaining between 90 to 
120 g/L. Antifibrinolitic therapy was based on 
10 mg/kg bolus of tranexamic acid during an-
esthesia induction followed by 10 mg kg-1 hour 
of continuous infusion kept until two hours 
after graft reperfusion.9 Contraindications to 
tranexamic administration were: Budd-Chiari 
syndrome, acute liver failure, early retransplan-
tation, simultaneous kidney and liver trans-
plantation, intraoperative dialysis and primary 
familial amyloidotic neuropathy.9 Two cohorts 
of patients were created based on preoperative 
plasma fibrinogen: Low fibrinogen (≤2 g/L) and 
standard fibrinogen (>2g/L).
Management during the procedure was proto-
colized for all patients. Rate of fluid infusion was 
kept at 5 mL Kg-1 h-1, avoiding colloids, calcium 
was administered to maintain ionized calcium 
levels at 1.2 mmol/L and sodium bicarbonate was 
infused to reach a pH greater than 7.30. Losses 
related to ascitis were corrected by the administra-
tion of 200 mL albumin 20%. Red blood cells 
packed (RBC’s) were given in order to maintain 
hemoglobin concentration at 90 g/L. Fresh frozen 
plasma was only administered when the interna-
tional normalized ratio (INR) resulted higher than 
1.8 and active bleeding in the surgical field was 
detected. Platelets were given in order to maintain 
a platelet count above 50x109 /L and 2 g of fibrin-
ogen was administered when needed to maintain 
plasma fibrinogen levels >1 g/L. 10 No intraop-
erative cell salvage of blood was used during sur-
gery. All patients were placed on a warm blanket 
of convection air (Warm-Touch, Mallinckrodt 
Medical). Liver allograft was preserved using Uni-
versity of Wisconsin solution. Prior to reperfusion 
of the graft, the liver was flushed with 1000 mL of 
Hartmann solution at 38 ºC in order to remove 
air and detritus through the entire inferior vena 
cava of the graft. Next, vascular stapler closed the 
distal end of the donor’s vena cava.
The following data were analyzed: patient 
characteristics, biochemical and coagulation 
tests, presence of reperfusion syndrome, total flu-
id therapy, postoperative creatinin and outcome. 
Samples for biochemical and coagulation deter-
minations were taken during different stages of 
the surgical procedure and 24 hours after the LT.
Variables and statistical analysis
The main variable of interest was the percent-
age of patients that do not require RBC’s intra-
operatively. The T-Student test or nonparamet-
ric Mann-Whitney U test were used to compare 
continuous variables depending on its distribu-
tion. Chi-square test was used to compare dis-
continuous variables. Statistical significance was 
set at P-value<0.05. Data are presented herein as 
an absolute number and percentage (%), mean 
and standard deviation or median and range.
Results
During the study period, 664 LT cases were 
performed. A total of 208 cases were excluded be-
cause of no or other antifibrinolitic therapy was 
applied or a different surgical technique was per-
formed. For all excluded patients, 29% did not 
receive any blood product intraoperatively. As a 
result, both preservation of vena cava and tran-
examic administration were fulfilled in 456 cases, 
in which 46.5% patients no blood product was 
used intraoperatively. When a propensity match-
ing analysis for hemoglobin concentration was 
applied, considering values between 90 and 120 
g/L, 190 patients resulted to be evaluated. Two 
groups were created according to the preoperative 
fibrinogen plasma level (cutting point based on a 
value of 2 g/L, which is the low normal value of 
our laboratory): the low fibrinogen group (61 cas-
es) and the standard fibrinogen group (129 cases).
P
O
O
F
M
IN
ER
VA
 M
ED
IC
A
PROFF ID.indd   1 10/09/10   14:28
PLASMA FIBRINOGEN LEVEL AND BLOOD TRANSFUSION IN LIVER TRANSPLANTATION COSTA
Vol. 79 - No. 4 MINERVA ANESTESIOLOGICA 3
ues. Use of RBC’s resulted significantly higher 
in the low fibrinogen group (median, 3 vs. 2). 
The number of patients with no blood product 
requirements was fewer in the low fibrinogen 
group (13% vs. 35%). However, intraoperative 
massive transfusion determined by more than 
10 RBC’s were similar in both groups. The use 
of fluids was similar in both groups (Table I). 
Patients’ characteristics, surgical and outcome 
data are represented in table 1. INR, PTT and 
platelets were significantly different between 
groups in contrast to the hemoglobin concentra-
tion that remained similar in both groups. There 
were no differences in the length of surgery, 
cold ischemia, reperfusion syndrome, the lowest 
temperature and pH recorded and calcium val-
Table I.—Patient’s characteristics, surgical procedure and outcome.
Low Fibrinogen  
(n=61)
Standard Fibrinogen 
(N.=129) P value
Age (years) 54±11 55±9 0.79
Gender (male/female) 39/21 88/41 0.621
Child A/B/C
median [range]
5/35/21 
 9 [5 to 13]
22/76/31 
 8 [5 to 14]
0.016 
0.004
MELD, UNOS modification (median [range])  11 [8 to 29]  10 [6 to 36]  0.230
Diagnose
Alcoholic Cirrhosis (%)
C-Virus Cirrhosis (%)
Biliar Primary Cirrhosis (%)
Hepatocelular carcinoma (%)
Retransplantation (%)
40 (65.5) 
4(6.5) 
— 
14 (23) 
3 (5)
71 (55) 
10 (7.75) 
4 (3) 
34 (26.5)
10 (7.75)
0.574
Preoperative
Previous laparotomy (%) 14 (23) 34 (26) 0.720
Partial portal vein thrombosis (%) 5 (8) 13 (10) 0.641
Renal replacement therapy (%) — 4 (3) 0.307
Sodium (mmol/L) 136±5 137±5 0.347
PTT ratio 1.49±0.37 1.23±0.27 <0.001
TP ratio 1.72±0.6 1.40±0.37 <0.001
Creatinine (mg/dL) 0.93±0.45 1±0.62 0.497
Hemoglobin (g/L) 104.2±8.6 105.6±8.3 0.286
Platelets count (103/mm3) 73.5±52 104±65 <0.001
Surgical data
Cold ischemia (minutes) (median [range]) 396 [210 to 855] 405 [205 to 856] 0.827
Length of procedure (minutes) 372±73 381±76 0.432
Reperfusion syndrome (%) 28 (46) 53 (41) 0.638
pH value after reperfusion (median [range]) 7.32 [7.16 to 7.48] 7.31 [7.13 to 7.44] 0.372
Calcium level after reperfusion (mmol/L) (median [range]) 1.20 [0.94 to 1.50] 1.24 [0.9 to 1.7] 0.075
Lowest temperature after reperfusion (cent degree) (median 
[range])
35.2 [33.6 to 36.8] 35.5 [32.6 to 36.1] 0.085
RBC’s Transfused units (median [range]) 3 [0 to 10] 2 [0 to 27] 0.004
FFP Transfused units (median [range]) 2 [0 to 11] 0 [0 to 34] <0.001
Platelets units (median [range]) 8 [0 to 40] 0 [0 to 25] <0.001
Fluid therapy (ml) (median [range]) 3760 [1000 to 5860] 4191 [1268 to 14565] 0.056
No RBC’s requirements (%) 8 (13) 45 (35) 0.007
>6 RBC’s transfused (%) 13 (21) 16 (12.5) 0.453
>10 RBC’s transfused (%) 1 (1.6) 3 (2.4) 0.924
Postoperative data
No RBC’s requirements 1st 24 h. (%) 46 (75) 97 (75) 0.974
Creatinine mg/dl 1.55±0.93 1.3±0.63 0.267
Renal replacement therapy (%) 2 (3.3) 5 (4) 1
Reoperation (%) 2 (3.3) 6 (4.6) 0.488
Acute Retransplantation (%) — 3 (2.3) 0.403
In hospital mortality (%) 6 (9.8) 16 (12.4) 0.809
Data expressed as: absolute number, (%); mean and standard deviation. PT: prothrombin time; PTT: activated partial thromboplastin time; RBCs: 
red blood cells; FFP: fresh frozen plasma.
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solely to specific haemostatic and coagulation 
profiles that were observed through the surgi-
cal procedure. Patient’s differences in relation 
to preoperative platelets could have influenced 
intraoperative bleeding; however, because of the 
high threshold for platelet transfusion deter-
mined by our protocol, most of patients in the 
low fibrinogen group received platelets. Fluid 
therapy regimen did not differ between groups 
indicating that hemodilution was not directly 
responsible of differences in bleeding and trans-
fusion requirements.
We did not use intraoperative cell salvage be-
cause this technique has been stated in LT to be 
cost-effective only in massive transfusion 12 and 
also, it may increase blood loss.13 In a series of 
patients with low transfusion rate, blood cell sal-
vaged was administered in only 35% of cases.14 
Intraoperative massive transfusion determined 
by more than 10 RBC’s was uncommon in our 
study, one patient in the low fibrinogen group 
and 3 patients in the standard fibrinogen group. 
This complication results from the confluence of 
several of these factors: a major surgical bleeding 
that occurs mostly at reperfusion of the graft, a 
severe hemodynamic disturbances and a signifi-
cant fibrinolyis.15-16 All these circumstances re-
quire an intensive treatment based on inotropic 
support, fluid therapy and blood components 
administration (red cells packed, plasma, fibrin-
ogen and platelets), and antifibrinolytic drug 
therapy.17 Patients with massive transfusion were 
out of the range in both fluid therapy and blood 
component usage, so that dilution coagulopathy, 
acidosis and in some cases mild hypothermia 
would occur, worsening both coagulopathy and 
hemodynamics, therefore preventive correction 
is fundamental.17
In the low fibrinogen group, two grams of fi-
brinogen were administered to 20 patients, four 
grams to one patient, six grams to one patient 
and eight grams to two patients; while, two 
grams of fibrinogen were administered to six 
patients and four grams to one patient in the 
standard group.
Fibrinogen profile is shown in Table II. Al-
though, plasma fibrinogen decrease occurred 
in both groups, the critical level of plasma fi-
brinogen for treatment (1 g/L) in the standard 
fibrinogen group was only reached after graft 
reperfusion in 7 cases (5.5%) vs. 24 cases (39%), 
p <0.001, in the low fibrinogen group.
Discussion
Our data suggest that preoperative plasma fi-
brinogen level of ≤2 g/L increases requirements 
for blood products during the surgical procedure 
of liver transplantation. A critical level of plasma 
fibrinogen (1g/L) was produced in LT at graft 
reperfusion in a significant percentage of pa-
tients when the preoperative plasma fibrinogen 
level was lower than 2 g/L. Use of RBC’s resulted 
significantly higher in the low fibrinogen group, 
even though fibrinogen was corrected.
Preservation of vena cava and antifibrinolitic 
drugs, have proved usefulness in reducing RBC’s 
requirements,3, 11 these aspects were considered 
when cohorts were selected. We did not observe 
differences in the length of surgical procedure, 
reperfusion syndrome was also present in a simi-
lar percentage of patients from both groups and 
no differences were observed in terms of acido-
sis correction, plasma calcium administered and 
control of temperature. Therefore, differences in 
blood product requirements might be attributed 
Table II.—Fibrinogen profile during liver transplantation procedure.
Low Fibrinogen
(N.=61)
High Fibrinogen  
(N.=129) P value
Preoperative fibrinogen g/L 1.63 [0.77 to 2] 3.4 [2.02 to 8.7] <0.001
Hepatectomy fibrinogen g/L 1.58 [0.9 to 2.96] 2.95 [1.11 to 7.22] <0.001
Anhepatic fibrinogen g/L 1.45 [0.9 to 3] 2.63 [1.2 to 7.2] <0.001
Reperfusion fibrinogen g/L 1.15 [0.3 to 2.52] 2.21 [0.6 to 6.9] <0.001
End-procedure fibrinogen g/L 1.32 [0.4 to 2.65] 2.24 [0.74 to 7] <0.001
24 hour postransplantation fibrinogen g/L 3.02 [1.32 to 6.7] 3.85 [1.5 to 8.24] <0.001
Data expressed as median [range].
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